APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucose Dependent Insulinotropic Receptor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Glucose Dependent Insulinotropic Receptor Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchGlucose Dependent Insulinotropic Receptor Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucose Dependent Insulinotropic Receptor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Glucose Dependent Insulinotropic Receptor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucose Dependent Insulinotropic Receptor Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucose Dependent Insulinotropic Receptor Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Glucose Dependent Insulinotropic Receptor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Glucose Dependent Insulinotropic Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Glucose Dependent Insulinotropic Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Glucose Dependent Insulinotropic Receptor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Glucose Dependent Insulinotropic Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Glucose Dependent Insulinotropic Receptor market include Takeda Pharmaceutical Co Ltd, Novartis AG, Merck & Co Inc, GlaxoSmithKline Plc, Amgen Inc, Yuhan Corp, Taisho Pharmaceutical Holdings Co Ltd, Kowa Co Ltd and Hyundai Pharmaceutical Co Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Glucose Dependent Insulinotropic Receptor market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glucose Dependent Insulinotropic Receptor and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glucose Dependent Insulinotropic Receptor revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Glucose Dependent Insulinotropic Receptor market.

Glucose Dependent Insulinotropic Receptor Segment by Company

Takeda Pharmaceutical Co Ltd

Novartis AG

Merck & Co Inc

GlaxoSmithKline Plc

Amgen Inc

Yuhan Corp

Taisho Pharmaceutical Holdings Co Ltd

Kowa Co Ltd

Hyundai Pharmaceutical Co Ltd

F. Hoffmann-La Roche Ltd

Dong-A Socio Holdings Co Ltd

CymaBay Therapeutics Inc

Arena Pharmaceuticals Inc

Glucose Dependent Insulinotropic Receptor Segment by Type

MBX-2982

HOB-047

HD-0471953

HD-0471042

GSK-2041706

DA-1241

Others

Glucose Dependent Insulinotropic Receptor Segment by Application

Type 2 Diabetes

Obesity

Chronic Obstructive Pulmonary Disease (COPD)

Dyslipidemia

Others

Glucose Dependent Insulinotropic Receptor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Glucose Dependent Insulinotropic Receptor status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Glucose Dependent Insulinotropic Receptor key companies, revenue, market share, and recent developments.

3. To split the Glucose Dependent Insulinotropic Receptor breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Glucose Dependent Insulinotropic Receptor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Glucose Dependent Insulinotropic Receptor significant trends, drivers, influence factors in global and regions.

6. To analyze Glucose Dependent Insulinotropic Receptor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucose Dependent Insulinotropic Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucose Dependent Insulinotropic Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucose Dependent Insulinotropic Receptor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Glucose Dependent Insulinotropic Receptor industry.

Chapter 3: Detailed analysis of Glucose Dependent Insulinotropic Receptor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Glucose Dependent Insulinotropic Receptor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Glucose Dependent Insulinotropic Receptor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Glucose Dependent Insulinotropic Receptor Industry Trends Table 2. Glucose Dependent Insulinotropic Receptor Industry Drivers Table 3. Glucose Dependent Insulinotropic Receptor Industry Opportunities and Challenges Table 4. Glucose Dependent Insulinotropic Receptor Industry Restraints Table 5. Global Glucose Dependent Insulinotropic Receptor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Glucose Dependent Insulinotropic Receptor Revenue Share by Company (2021-2026) Table 7. Global Glucose Dependent Insulinotropic Receptor Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Glucose Dependent Insulinotropic Receptor Key Company Manufacturing Base & Headquarters Table 9. Global Glucose Dependent Insulinotropic Receptor Company, Product Type & Application Table 10. Global Glucose Dependent Insulinotropic Receptor Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Glucose Dependent Insulinotropic Receptor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of MBX-2982 Table 15. Significant Companies of HOB-047 Table 16. Significant Companies of HD-0471953 Table 17. Significant Companies of HD-0471042 Table 18. Significant Companies of GSK-2041706 Table 19. Significant Companies of DA-1241 Table 20. Significant Companies of Others Table 21. Global Glucose Dependent Insulinotropic Receptor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Glucose Dependent Insulinotropic Receptor Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Glucose Dependent Insulinotropic Receptor Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Type (2021-2026) Table 25. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Type 2 Diabetes Table 27. Significant Companies of Obesity Table 28. Significant Companies of Chronic Obstructive Pulmonary Disease (COPD) Table 29. Significant Companies of Dyslipidemia Table 30. Significant Companies of Others Table 31. Global Glucose Dependent Insulinotropic Receptor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Glucose Dependent Insulinotropic Receptor Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Glucose Dependent Insulinotropic Receptor Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Application (2021-2026) Table 35. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Application (2027-2032) Table 36. Global Glucose Dependent Insulinotropic Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Glucose Dependent Insulinotropic Receptor Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Region (2021-2026) Table 39. Global Glucose Dependent Insulinotropic Receptor Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Region (2027-2032) Table 41. Global Glucose Dependent Insulinotropic Receptor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Glucose Dependent Insulinotropic Receptor Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Glucose Dependent Insulinotropic Receptor Sales Value Market Share by Country (2021-2026) Table 44. Global Glucose Dependent Insulinotropic Receptor Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Glucose Dependent Insulinotropic Receptor Sales Value Market Share by Country (2027-2032) Table 46. Takeda Pharmaceutical Co Ltd Company Information Table 47. Takeda Pharmaceutical Co Ltd Business Overview Table 48. Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 50. Takeda Pharmaceutical Co Ltd Recent Development Table 51. Novartis AG Company Information Table 52. Novartis AG Business Overview Table 53. Novartis AG Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio Table 55. Novartis AG Recent Development Table 56. Merck & Co Inc Company Information Table 57. Merck & Co Inc Business Overview Table 58. Merck & Co Inc Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 60. Merck & Co Inc Recent Development Table 61. GlaxoSmithKline Plc Company Information Table 62. GlaxoSmithKline Plc Business Overview Table 63. GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 65. GlaxoSmithKline Plc Recent Development Table 66. Amgen Inc Company Information Table 67. Amgen Inc Business Overview Table 68. Amgen Inc Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 70. Amgen Inc Recent Development Table 71. Yuhan Corp Company Information Table 72. Yuhan Corp Business Overview Table 73. Yuhan Corp Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio Table 75. Yuhan Corp Recent Development Table 76. Taisho Pharmaceutical Holdings Co Ltd Company Information Table 77. Taisho Pharmaceutical Holdings Co Ltd Business Overview Table 78. Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 80. Taisho Pharmaceutical Holdings Co Ltd Recent Development Table 81. Kowa Co Ltd Company Information Table 82. Kowa Co Ltd Business Overview Table 83. Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 85. Kowa Co Ltd Recent Development Table 86. Hyundai Pharmaceutical Co Ltd Company Information Table 87. Hyundai Pharmaceutical Co Ltd Business Overview Table 88. Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 90. Hyundai Pharmaceutical Co Ltd Recent Development Table 91. F. Hoffmann-La Roche Ltd Company Information Table 92. F. Hoffmann-La Roche Ltd Business Overview Table 93. F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 95. F. Hoffmann-La Roche Ltd Recent Development Table 96. Dong-A Socio Holdings Co Ltd Company Information Table 97. Dong-A Socio Holdings Co Ltd Business Overview Table 98. Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio Table 100. Dong-A Socio Holdings Co Ltd Recent Development Table 101. CymaBay Therapeutics Inc Company Information Table 102. CymaBay Therapeutics Inc Business Overview Table 103. CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 105. CymaBay Therapeutics Inc Recent Development Table 106. Arena Pharmaceuticals Inc Company Information Table 107. Arena Pharmaceuticals Inc Business Overview Table 108. Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio Table 110. Arena Pharmaceuticals Inc Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Glucose Dependent Insulinotropic Receptor Product Image Figure 2. Global Glucose Dependent Insulinotropic Receptor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucose Dependent Insulinotropic Receptor Market Size (2021-2032) & (US$ Million) Figure 4. Global Glucose Dependent Insulinotropic Receptor Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. MBX-2982 Image Figure 8. HOB-047 Image Figure 9. HD-0471953 Image Figure 10. HD-0471042 Image Figure 11. GSK-2041706 Image Figure 12. DA-1241 Image Figure 13. Others Image Figure 14. Global Glucose Dependent Insulinotropic Receptor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Glucose Dependent Insulinotropic Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Type (2021-2032) Figure 17. Type 2 Diabetes Image Figure 18. Obesity Image Figure 19. Chronic Obstructive Pulmonary Disease (COPD) Image Figure 20. Dyslipidemia Image Figure 21. Others Image Figure 22. Global Glucose Dependent Insulinotropic Receptor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Glucose Dependent Insulinotropic Receptor Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Application (2021-2032) Figure 25. Global Glucose Dependent Insulinotropic Receptor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032) & (US$ Million) Figure 28. North America Glucose Dependent Insulinotropic Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Glucose Dependent Insulinotropic Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Glucose Dependent Insulinotropic Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032) & (US$ Million) Figure 34. South America Glucose Dependent Insulinotropic Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Glucose Dependent Insulinotropic Receptor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • MBX-2982
  • HOB-047
  • HD-0471953
  • HD-0471042
  • GSK-2041706
  • DA-1241
  • Others
Applications
  • Type 2 Diabetes
  • Obesity
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Dyslipidemia
  • Others
Companies covered
  • Takeda Pharmaceutical Co Ltd
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Yuhan Corp
  • Taisho Pharmaceutical Holdings Co Ltd
  • Kowa Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Dong-A Socio Holdings Co Ltd
  • CymaBay Therapeutics Inc
  • Arena Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Glucose Dependent Insulinotropic Receptor Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Glucose Dependent Insulinotropic Receptor Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Glucose Dependent Insulinotropic Receptor Market Dynamics
  1. 2.1 Glucose Dependent Insulinotropic Receptor Industry Trends
  2. 2.2 Glucose Dependent Insulinotropic Receptor Industry Drivers
  3. 2.3 Glucose Dependent Insulinotropic Receptor Industry Opportunities and Challenges
  4. 2.4 Glucose Dependent Insulinotropic Receptor Industry Restraints
3 Glucose Dependent Insulinotropic Receptor Market by Company
  1. 3.1 Global Glucose Dependent Insulinotropic Receptor Company Revenue Ranking in 2025
  2. 3.2 Global Glucose Dependent Insulinotropic Receptor Revenue by Company (2021-2026)
  3. 3.3 Global Glucose Dependent Insulinotropic Receptor Company Ranking (2024-2026)
  4. 3.4 Global Glucose Dependent Insulinotropic Receptor Company Manufacturing Base and Headquarters
  5. 3.5 Global Glucose Dependent Insulinotropic Receptor Company Product Type and Application
  6. 3.6 Global Glucose Dependent Insulinotropic Receptor Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Glucose Dependent Insulinotropic Receptor Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Glucose Dependent Insulinotropic Receptor Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Glucose Dependent Insulinotropic Receptor Market by Type
  1. 4.1 Glucose Dependent Insulinotropic Receptor Type Introduction
  2. 4.1.1 MBX-2982
  3. 4.1.2 HOB-047
  4. 4.1.3 HD-0471953
  5. 4.1.4 HD-0471042
  6. 4.1.5 GSK-2041706
  7. 4.1.6 DA-1241
  8. 4.1.7 Others
  9. 4.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Type
  10. 4.2.1 Global Glucose Dependent Insulinotropic Receptor Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Type (2021-2032)
  12. 4.2.3 Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Type (2021-2032)
5 Glucose Dependent Insulinotropic Receptor Market by Application
  1. 5.1 Glucose Dependent Insulinotropic Receptor Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Obesity
  4. 5.1.3 Chronic Obstructive Pulmonary Disease (COPD)
  5. 5.1.4 Dyslipidemia
  6. 5.1.5 Others
  7. 5.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Application
  8. 5.2.1 Global Glucose Dependent Insulinotropic Receptor Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Application (2021-2032)
  10. 5.2.3 Global Glucose Dependent Insulinotropic Receptor Sales Value Share by Application (2021-2032)
6 Glucose Dependent Insulinotropic Receptor Regional Value Analysis
  1. 6.1 Global Glucose Dependent Insulinotropic Receptor Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Region (2021-2032)
  3. 6.2.1 Global Glucose Dependent Insulinotropic Receptor Sales Value by Region: 2021-2026
  4. 6.2.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032)
  7. 6.3.2 North America Glucose Dependent Insulinotropic Receptor Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032)
  10. 6.4.2 Europe Glucose Dependent Insulinotropic Receptor Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Glucose Dependent Insulinotropic Receptor Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032)
  16. 6.6.2 South America Glucose Dependent Insulinotropic Receptor Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Glucose Dependent Insulinotropic Receptor Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Glucose Dependent Insulinotropic Receptor Sales Value Share by Country, 2025 VS 2032
7 Glucose Dependent Insulinotropic Receptor Country-level Value Analysis
  1. 7.1 Global Glucose Dependent Insulinotropic Receptor Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Country (2021-2032)
  3. 7.2.1 Global Glucose Dependent Insulinotropic Receptor Sales Value by Country (2021-2026)
  4. 7.2.2 Global Glucose Dependent Insulinotropic Receptor Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Glucose Dependent Insulinotropic Receptor Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Glucose Dependent Insulinotropic Receptor Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Glucose Dependent Insulinotropic Receptor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Co Ltd
  2. 8.1.1 Takeda Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Takeda Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co Inc
  14. 8.3.1 Merck & Co Inc Company Information
  15. 8.3.2 Merck & Co Inc Business Overview
  16. 8.3.3 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  18. 8.3.5 Merck & Co Inc Recent Developments
  19. 8.4 GlaxoSmithKline Plc
  20. 8.4.1 GlaxoSmithKline Plc Company Information
  21. 8.4.2 GlaxoSmithKline Plc Business Overview
  22. 8.4.3 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio
  24. 8.4.5 GlaxoSmithKline Plc Recent Developments
  25. 8.5 Amgen Inc
  26. 8.5.1 Amgen Inc Company Information
  27. 8.5.2 Amgen Inc Business Overview
  28. 8.5.3 Amgen Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  30. 8.5.5 Amgen Inc Recent Developments
  31. 8.6 Yuhan Corp
  32. 8.6.1 Yuhan Corp Company Information
  33. 8.6.2 Yuhan Corp Business Overview
  34. 8.6.3 Yuhan Corp Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio
  36. 8.6.5 Yuhan Corp Recent Developments
  37. 8.7 Taisho Pharmaceutical Holdings Co Ltd
  38. 8.7.1 Taisho Pharmaceutical Holdings Co Ltd Company Information
  39. 8.7.2 Taisho Pharmaceutical Holdings Co Ltd Business Overview
  40. 8.7.3 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  42. 8.7.5 Taisho Pharmaceutical Holdings Co Ltd Recent Developments
  43. 8.8 Kowa Co Ltd
  44. 8.8.1 Kowa Co Ltd Company Information
  45. 8.8.2 Kowa Co Ltd Business Overview
  46. 8.8.3 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  48. 8.8.5 Kowa Co Ltd Recent Developments
  49. 8.9 Hyundai Pharmaceutical Co Ltd
  50. 8.9.1 Hyundai Pharmaceutical Co Ltd Company Information
  51. 8.9.2 Hyundai Pharmaceutical Co Ltd Business Overview
  52. 8.9.3 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  54. 8.9.5 Hyundai Pharmaceutical Co Ltd Recent Developments
  55. 8.10 F. Hoffmann-La Roche Ltd
  56. 8.10.1 F. Hoffmann-La Roche Ltd Company Information
  57. 8.10.2 F. Hoffmann-La Roche Ltd Business Overview
  58. 8.10.3 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  59. 8.10.4 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  60. 8.10.5 F. Hoffmann-La Roche Ltd Recent Developments
  61. 8.11 Dong-A Socio Holdings Co Ltd
  62. 8.11.1 Dong-A Socio Holdings Co Ltd Company Information
  63. 8.11.2 Dong-A Socio Holdings Co Ltd Business Overview
  64. 8.11.3 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
  66. 8.11.5 Dong-A Socio Holdings Co Ltd Recent Developments
  67. 8.12 CymaBay Therapeutics Inc
  68. 8.12.1 CymaBay Therapeutics Inc Company Information
  69. 8.12.2 CymaBay Therapeutics Inc Business Overview
  70. 8.12.3 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  72. 8.12.5 CymaBay Therapeutics Inc Recent Developments
  73. 8.13 Arena Pharmaceuticals Inc
  74. 8.13.1 Arena Pharmaceuticals Inc Company Information
  75. 8.13.2 Arena Pharmaceuticals Inc Business Overview
  76. 8.13.3 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
  78. 8.13.5 Arena Pharmaceuticals Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst